» Articles » PMID: 12431991

Tumor Necrosis Factor-regulated Biphasic Activation of NF-kappa B is Required for Cytokine-induced Loss of Skeletal Muscle Gene Products

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2002 Nov 15
PMID 12431991
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

NF-kappaB activation is classically defined as a transient response initiated by the degradation of IkappaB inhibitor proteins leading to nuclear import of NF-kappaB and culminating with the resynthesis of IkappaBalpha and subsequent inactivation of the transcription factor. Although this type of regulation is considered the paradigm for NF-kappaB activation, other regulatory profiles are known to exist. By far the most common of these is chronic or persistent activation of NF-kappaB. In comparison, regulation of NF-kappaB in a biphasic manner represents a profile that is scarcely documented and whose biological significance remains poorly understood. Here we show using differentiated skeletal muscle cells, that tumor necrosis factor (TNF) induces NF-kappaB activation in a biphasic manner. Unlike the first transient phase, which is terminated within 1 h of cytokine addition, the second phase persists for an additional 24-36 h. Biphasic activation is mediated at both the levels of NF-kappaB DNA binding and transactivation function, and both phases are dependent on the IKK/26 S proteasome pathway. We find that regulation of the first transient phase is mediated by the degradation and subsequent resynthesis of IkappaBalpha, as well as by a TNF-induced expression of A20. Second phase activity correlates with persistent down-regulation of both IkappaBalpha and IkappaBbeta proteins, derived from a continuous TNF signal. Finally, we demonstrate that inhibition of NF-kappaB prior to initiation of the second phase of activity inhibits cytokine-mediated loss of muscle proteins. We propose that the biphasic activation of NF-kappaB in response to TNF may play a key regulatory role in skeletal muscle wasting associated with cachexia.

Citing Articles

Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting.

Nevi L, Pollanen N, Penna F, Caretti G Int J Mol Sci. 2023; 24(22).

PMID: 38003594 PMC: 10671811. DOI: 10.3390/ijms242216404.


Role of Brain Liver X Receptor in Parkinson's Disease: Hidden Treasure and Emerging Opportunities.

Alnaaim S, Al-Kuraishy H, Alexiou A, Papadakis M, Saad H, El-Saber Batiha G Mol Neurobiol. 2023; 61(1):341-357.

PMID: 37606719 PMC: 10791998. DOI: 10.1007/s12035-023-03561-y.


NF-κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective.

Alrouji M, Al-Kuraishy H, Al-Gareeb A, Alexiou A, Papadakis M, Jabir M J Cell Mol Med. 2023; 27(13):1775-1789.

PMID: 37210624 PMC: 10315781. DOI: 10.1111/jcmm.17784.


Parkinson's Disease Risk and Hyperhomocysteinemia: The Possible Link.

Al-Kuraishy H, Al-Gareeb A, Elewa Y, Zahran M, Alexiou A, Papadakis M Cell Mol Neurobiol. 2023; 43(6):2743-2759.

PMID: 37074484 PMC: 10333143. DOI: 10.1007/s10571-023-01350-8.


Betaine Treatment Prevents TNF-α-Mediated Muscle Atrophy by Restoring Total Protein Synthesis Rate and Morphology in Cultured Myotubes.

Di Credico A, Gaggi G, Izzicupo P, Vitucci D, Buono P, Di Baldassarre A J Histochem Cytochem. 2023; 71(4):199-209.

PMID: 37013268 PMC: 10149894. DOI: 10.1369/00221554231165326.